This page shows the latest Inviragen news and features for those working in and with pharma, biotech and healthcare.
Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.
Takeda buys vaccines specialist Inviragen. Acquires vaccine candidates against dengue fever and hand, foot and mouth disease in $250m deal. ... The biopharma company Inviragen, which has operations in the US and Singapore, will receive an upfront payment
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
UAE based regional company $40m $244m option for 52%. 284. Inviragen/ Takeda.
targets from Abide; Takeda's $250m acquisition of Inviragen; GSK's $325m acquisition of the vaccine platform technology company, Okairos; and BMS's $112m licence for antibody conjugates from Ambrx.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...